Streetbeat News

SOPH

SOPHiA GENETICS SA

https://www.sophiagenetics.com

Industry

Medical - Healthcare Information Services

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Open

3.33

Mkt cap

214M

Volume

43K

High

3.35

P/E Ratio

-3.00

52-wk high

7.37

Low

3.20

Div yield

N/A

52-wk low

2.70

Sophia Genetics (NASDAQ:SOPH) reported Q2 2024 GAAP EPS of $(0.23), beating the estimate of $(0.28). However, sales of $15.808M missed the $17.400M estimate, though they increased by 5.01% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:48 am

Guggenheim has initiated coverage on Sophia Genetics (NASDAQ:SOPH) with a Buy rating and set a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:11 am

SOPHiA GENETICS (NASDAQ:SOPH) has announced a new Residual Acute Myeloid (RAM) Application to monitor Acute Myeloid Leukemia (AML). This new tool expands their oncology portfolio and will be available globally this summer.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:21 am

SOPHiA GENETICS (NASDAQ:SOPH) has announced that Kepler Uniklinikum, Austria's second largest hospital, is now using its SOPHiA DDM™ Platform for next-generation sequencing (NGS) testing and diagnostics of blood-related cancers. This implementation aims to enhance the hospital's in-house NGS testing capabilities and expand its offerings to patients with blood cancers and disorders.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 10:06 am

Bank of Montreal (NYSE:BMO) shares fell 7.1% after reporting worse-than-expected Q2 earnings. Other notable stock movements include ReShape Lifesciences Inc. (NASDAQ:RSLS) jumping 82.8% due to a new patent, and Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) falling 38.8% after disappointing revenue results.

Portfolio Pulse from Avi Kapoor

May 29, 2024 | 5:28 pm

SOPHiA GENETICS is collaborating with Microsoft and NVIDIA to develop a scalable whole genome sequencing solution, aiming for availability by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 4:51 pm

Heico Corporation (HEI) posted strong second-quarter earnings, leading to a 4.6% rise in its stock price. Other notable gainers include AST SpaceMobile (ASTS), Ooma (OOMA), Surmodics (SRDX), Abercrombie & Fitch (ANF), and DICK'S Sporting Goods (DKS), among others.

Portfolio Pulse from Avi Kapoor

May 29, 2024 | 2:38 pm

SOPHiA GENETICS has reaffirmed its fiscal year 2024 revenue guidance to be in the range of $78 million to $81 million, aligning closely with the analyst estimate of $79.168 million.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:44 am

Sophia Genetics reported Q1 2024 earnings with a GAAP EPS of $(0.21), surpassing the $(0.28) estimate, indicating a 25% beat and a 32.26% improvement from last year's $(0.31) per share. However, their Q1 sales of $15.779M fell short of the $16.467M estimate by 4.18%, despite being a 12.98% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 10:48 am

SOPHiA GENETICS announced its collaboration with Unilabs, utilizing the SOPHiA DDM Platform for HRD-status testing in solid tumors, aiming to expedite analysis across Unilabs' network in Switzerland.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 10:08 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.